CagriSema (Cagrilintide + Semaglutide)
Why this combination
CagriSema combines a long-acting amylin analog (cagrilintide) with a GLP-1 agonist (semaglutide), each titrated toward 2.4 mg weekly. The two appetite mechanisms — amylin-mediated and GLP-1-mediated satiety — are additive, and the combination has advanced through Phase 3 (REDEFINE) as a fixed-dose product.
It is the most clinically substantiated dual-peptide weight-management combination on this list, though the fixed combination itself remains investigational pending regulatory review.
Per-compound dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Cagrilintide | 0.3 → 2.4 mg | Once weekly | Titrated in parallel with semaglutide. |
| Semaglutide | 0.25 → 2.4 mg | Once weekly | Standard semaglutide titration. |
Reconstitution math
For educational and research reference only. Not intended for human consumption, not medical advice. Compounds discussed are sold and used for laboratory research purposes only.
Separate vials
Cagrilintide — 10 mg + 2 mL → 5,000 mcg/mL; 2,400 mcg = 0.48 mL (48 units).
Semaglutide — 10 mg + 2 mL → 5,000 mcg/mL; 2,400 mcg = 0.48 mL (48 units).
Running separate vials lets each be titrated on its own schedule, which is the safer approach during dose escalation.
Pre-blended (single vial)
Pre-blending at full 2.4/2.4 mg doses is awkward (a combined draw approaches a full 100-unit syringe), so blending is best reserved for the lower titration phase.
Early-phase example: combine cagrilintide 5 mg + semaglutide 5 mg and add 5 mL → each is 1,000 mcg/mL, so a 0.3 mL draw (30 units) delivers 300 mcg of each — suitable for the 0.3 mg starting phase.
Verify any blend with the reconstitution calculator before dosing — concentrations change for every compound when you alter the water volume.
Cycle length & alternatives
- Cycle length
- Long-term weight-management use in trials (≥68 weeks); titrated over the first ~16–20 weeks.
- Compared to alternatives
- Versus semaglutide alone, CagriSema adds amylin-mediated satiety for greater reported weight loss. Versus tirzepatide, it reaches dual-mechanism appetite control through two molecules rather than one.
Sources & references
Frequently asked questions
Is CagriSema approved?
The individual components are studied separately; the fixed cagrilintide + semaglutide combination has progressed through Phase 3 (REDEFINE) but remains investigational pending regulatory decisions. Treat efficacy figures as trial-derived.
Should the two be titrated together?
In trials they are titrated in parallel toward 2.4 mg each. Running separate vials during escalation makes it easier to back off one component if tolerability becomes an issue.
For educational and research reference only. Not intended for human consumption, not medical advice. Compounds discussed are sold and used for laboratory research purposes only.
Related stacks
Cagrilintide + Tirzepatide
This combination layers three appetite mechanisms by pairing the long-acting amylin analog cagrilintide with the dual-incretin agonist tirzepatide (GIP + GLP-1). The logic directly mirrors CagriSema — which combines amylin with GLP-1 — but substitutes tirzepatide, whose added GIP activity already produces some of the largest weight-loss figures of any approved single molecule (up to roughly 21% in SURMOUNT-1). Stacking amylin-mediated satiety on top is intended to push appetite suppression further still.
Cagrilintide + Retatrutide
This is the most aggressive weight-loss combination on paper: it stacks the long-acting amylin analog cagrilintide on top of retatrutide, the triple-G agonist that activates the GIP, GLP-1, and glucagon receptors at once. Retatrutide alone produced the largest weight reductions reported for any pharmacological agent in its Phase 2 trial — about 24% at 48 weeks, with the curve still falling — and the glucagon component adds an energy-expenditure mechanism on top of the appetite suppression shared with other incretins. Adding amylin-mediated satiety layers a fourth, mechanistically distinct hunger signal onto that base.